PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2017 February 28; 8(9): 15732–15743.
Published online 2017 February 2. doi:  10.18632/oncotarget.14997
PMCID: PMC5362519

SerpinB3 upregulates the Cyclooxygenase-2 / β-Catenin positive loop in colorectal cancer

Abstract

Colorectal cancer is characterized by aberrant Cyclooxigenase-2 (COX-2) and β-Catenin pathways. Recently, the protease inhibitor SerpinB3 has been described overexpressed in more advanced stages of this tumor. Aim of the study was to explore the possible relationship between these molecules in this setting. We evaluated colorectal cancer specimens from 105 patients and a positive correlation between SerpinB3, COX-2 and β-Catenin expression was observed, with higher levels in tumor than in adjacent tissue. The highest levels were associated with pathologic parameters of poor prognosis, including vascular invasion, lymph node metastasis and perineural invasion. The molecular and protein profiles of COX-2 and β-Catenin were analyzed in cell lines with different expression of SerpinB3. In those with high expression of SerpinB3, COX-2 and β-Catenin were higher than in controls. Cells with high levels of SerpinB3 showed higher proliferation and invasion compared to controls. In conclusion, in colorectal cancer SerpinB3, COX-2 and β-Catenin are positively correlated and associated with more advanced tumor stage. The in vitro experimental results support a driving role of SerpinB3 in the upregulation of COX-2/ β-Catenin positive loop, associated with a more aggressive cellular phenotype.

Keywords: colorectal cancer, SerpinB3, COX-2, β-Catenin, tumor stage

INTRODUCTION

Colorectal cancer (CRC) is a multistep process characterized by genetic aberrations of several oncogenes. In particular, many studies have demonstrated that K-RAS mutations occur in 30% to 50% of colorectal tumors [17]. Recently, Catanzaro et al. have demonstrated that mutant K-RAS induces inflammatory cytokine production and tumorigenesis by upregulating SerpinB3 and SerpinB4 isoforms, both members of the serine/cysteine protease inhibitors family [8]. These serpins have been previously reported to stimulate liver carcinogenesis [9]. Indeed, their over-expression promotes cell survival through the inhibition of apoptosis [10, 11], increases cell proliferation and induces epithelial-mesenchymal transition (EMT) [12, 13]. In liver cancer with poor prognosis SerpinB3 was associated with TGF-β1 and β-Catenin expression [14]. One of the major pathways involved in EMT regulation is the Wnt/β-Catenin pathway [15, 16] which is also one of the most important pathways associated with colorectal cancer progression and it was shown to be constitutively activated in about 90% of sporadic colorectal tumors [1719]. In particular, β-Catenin induces the over-expression of cyclooxygenase-2 (COX-2 or PTGS2). COX-2 enhances prostaglandin E2 (PGE2) levels, can induce inflammation, cell proliferation, angiogenesis, EMT and invasiveness and it was found increased in more advanced forms of breast, colon, biliary tract, skin, lung and liver cancer [2023]. COX-2/PGE2 may exert their pro-oncogenic action through the stimulation of the β-Catenin/LEF1/TCF-mediated transcription, which is known to activate colorectal carcinogenesis [24]. In addition, recent studies have shown that β-Catenin and COX-2 are often co-expressed in cancer cells and that the latter is up-regulated by nuclear β-Catenin accumulation [2529].

Aim of the present study was to clarify the relationship between SerpinB3, COX-2 and β-Catenin in colorectal cancer analyzing tumor samples of well characterized patients and cell lines with different expression of SerpinB3.

RESULTS

SerpinB3, COX-2 and β-Catenin mRNA expression in colorectal cancer specimens

The absolute quantification of SerpinB3, COX-2 and β-Catenin mRNA expression, normalized by the HPRT1 housekeeping gene, was assessed in 105 primary human colorectal tumors (T) and in their corresponding adjacent non-tumor mucosa (N) by quantitative Real-Time PCR. A significant higher expression of all three genes was detected in tumor tissue, compared to matched non-tumor tissue (Figure (Figure1,1, upper panel). In line with these results, a significant correlation was found between the expression of the three molecules that was higher in tumor specimens, especially between COX-2 and SerpinB3 (Figure (Figure1,1, lower panels). In the adenomas transcript levels of the three genes were similar to those found in the colonic adjacent mucosa (Figure (Figure1,1, upper panel). Despite the limited number of cases, it is worth to note that SerpinB3 values progressively increased from patient with low to high grade displasia, while the behaviour of COX-2 and β-Catenin were not related with the degree of displasia (Supplementary Table 1).

Figure 1
SerpinB3, COX-2 and β-Catenin mRNA expression levels in colorectal cancer tissue

Correlation of SerpinB3 mRNA with pathological data

In order to further elucidate the potential involvement of SerpinB3 in colorectal tumor progression, we analyzed its expression levels in relation to disease stage. A significant increase in SerpinB3 expression levels was found in more advanced stages (III-IV), both in tumor and non-tumor samples, although absolute values were higher in tumor specimens (Figure (Figure2A).2A). COX-2 and β-Catenin showed similar expression profiles. LabChip® Systems results confirmed quantitative data, as shown in Supplementary Figure 1.

Figure 2
Correlation between SerpinB3, COX-2, β-Catenin expression and tumor stage

Immunohistochemistry results were in line with transcription data (Figure (Figure2B)2B) and the highest protein expression of all three molecules was found in stage IV tumors, while trivial levels were observed in stage I tumors, as reported in Figure Figure2B.2B. It is worth to note that in sequential tumor sections the highest signal of SerpinB3 was detected in areas showing high positivity for COX-2 and β-Catenin, indicating a possible relationship among these molecules. In sections of non-tumor mucosa SerpinB3 was barely detected and a faint positivity of COX-2 and β-Catenin was observed mainly in the cytoplasm (Supplementary Figure 2).

To assess the prognostic value of SerpinB3, COX-2 and β-Catenin, their expression in tumor specimens was analyzed in relation to pathologic parameters of poor prognosis, including vascular invasion, lymph node metastasis and perineural invasion. Tumor specimens positive for these pathologic parameters had significantly higher expression of SerpinB3, COX-2 and β-Catenin, compared to negative ones (Figure (Figure3).3). In the corresponding non tumoral tissue the expression of SerpinB3 and COX-2, but not that of β-Catenin, was significantly higher in patients with lymph node metastasis, while vascular and perineural invasion did not affect the expression of these molecules (Supplementary Figure 3).

Figure 3
SerpinB3, COX-2 and β-Catenin expression in tumor specimens in relation with histological parameters of poor prognosis

Expression in cell cultures

In preliminary experiments we have analyzed SerpinB3 expression in different human colon carcinoma cell lines (RKO-E6, SW48, HCT 116, HT29 and HTC 15). HT29 cells showed a strong SerpinB3 expression signal, while in the other cell lines only a weak positivity was observed. For this reason, we have chosen HT29 as positive colon cell line and HTC15 as negative control cell line. The previously studied HepG2/SerpinB3 cell line that stably expresses SerpinB3 [12] was used as further positive control and HepG3 cells transfected with the plasmid vector alone were used as additional negative control (HepG3/Control). Fluorescence and ROI data confirmed the correlation of this serpin with the extent of β-Catenin and COX-2 expression (Figure (Figure44 and Supplementary Figure 4).

Figure 4
Immunofluorescence analysis of SerpinB3, COX-2 and β-Catenin

Time course analysis revealed that COX-2 and β-Catenin genes were over-expressed at transcription and protein level in cells with high levels of SerpinB3 (Figure (Figure5),5), while lower levels of these molecules were found in cells with low SerpinB3. HT29 and HepG2/SerpinB3 cell lines showed indeed similar profiles, as occurred for HTC15 and HepG2/Control cell lines.

Figure 5
Profile of expression of SerpinB3, COX-2 and β-Catenin in cell lines

HT29 cells, expressing high levels of SerpinB3, showed higher proliferation rate and invasion ability, compared with HTC15 cells (Supplementary Figure 5). The effect of the exposure to recombinant SerpinB3 was also assessed in HTC15 and HT29 cell lines. A significant increase of proliferation, but not of invasion, was observed in both cell lines exposed to SerpinB3 and the result was more prominent in the HT29 cell line (Supplementary Figure 5). These findings recall previous data obtained in HepG2 cells, however, in the hepatoma cell line exogenous SerpinB3 determined also a significant increase of invasion [12].

The exposure to recombinant SerpinB3 did not determine any significant increase of β–Catenin, mainly detected in the cytosolic fractions, and of COX-2, mainly detected in the nuclei (Supplementary Figure 6). It is worth to note that this exocrine stimulation determined also some increase of nuclear SerpinB3, especially in the HT29 cell line. This nuclear form of the serpin showed higher molecular weight, compared with the cytosolic counterpart, suggesting its binding to another, not yet characterized, molecule and this finding deserves further studies.

DISCUSSION

Several studies have shown the important role of COX-2 and β-Catenin proteins in colorectal tumorigenesis. Recently, SerpinB3/4 isoforms have been found upregulated by oncogenic Ras in advanced stages of colorectal and pancreatic tumors [8]. To our experience, this is the first study in which SerpinB3 has been analyzed in colorectal cancer and correlated with the expression of COX-2 and β-Catenin. Previous observations indicate that COX-2 and β-Catenin expression was higher in poorly differentiated stages than in well or moderately differentiated stages [3032]. Our results have demonstrated that SerpinB3, COX-2 and β-Catenin were significantly higher in tumor tissues, compared to the normal counterpart and that their expression progressively increased according to tumor stage. Moreover, tumor specimens with pathologic parameters of poor prognosis, including vascular invasion, lymph node metastasis and perineural invasion showed significantly higher expression of all these three molecules.

In vitro results suggest that SerpinB3 increases cell proliferation and invasion and that this serpin is the driver of COX-2 and β-Catenin behaviour. Their expression was indeed dependent on the presence of this serpin. It should be noted that the HT-29 cell line, overexpressing SerpinB3, shows enrichment of cancer stem cell markers [33, 34] and this could be one of the possible explanations for its increased aggressiveness and/or its increased expression of SerpinB3. These results are in agreement with our previous study carried out in hepatocellular carcinomas, where high expression of SerpinB3 in neoplastic livers was characterized by high β-Catenin levels and more disseminative clinical phenotype, evidenced as more frequent early tumour recurrence [14]. In addition, SerpinB3 has been found expressed also in hepatic progenitor cells and it is well known that tumors showing hepatic progenitor cell features have a worse prognosis and a higher recurrence rate compared to tumors lacking these characteristics [35].

On the basis of the results obtained in our study, we could hypothesize that SerpinB3 may be involved in the induction of β-Catenin accumulation that promotes the activation of COX-2/PGE2 axis which, in turn, contributes to maintain their positive loop (Figure (Figure6).6). The best proof of concept of this novel nexus could be supported by the use of a SerpinB3 inhibitor, but at best of our knowledge, no inhibitors of this serpin have been reported yet in the literature. In addition, we cannot exclude that SerpinB3 may lead COX-2 induction also through the activation of NF-kB dependent inflammatory cascade [36], as a result of the block of protein turnover determined by this serpin.

Figure 6
The proposed mechanism the COX-2/ β-Catenin positive loop upregulation by SerpinB3

In conclusion, in patients with colorectal cancer the expression of SerpinB3 was higher in more advanced tumor stages and it was correlated with histological parameters of poor prognosis. This serpin was shown to induce the expression of β-Catenin and of COX-2, molecules already identified as markers of poor prognosis, and it might be considered as a novel molecular target suitable for colorectal cancer therapy.

MATERIALS AND METHODS

Patient Characteristics

Surgical samples were obtained from 105 patients who underwent surgery for colorectal cancer as first line therapy at the Surgical Clinic I of the Padua University Hospital between 2002 and 2005. Table Table11 summarizes clinical and histopathological features of patients included in the study. Tumor and the adjacent non tumor tissue samples were collected at the time of surgical resection and part was formalin fixed and paraffin embedded, while the remaining part was immediately shock-frozen at -80°C for further analysis.

Table 1
Clinical and histopathological characteristics of the patients included in the study

Pathological samples were classified according to the AJCC staging classification, using the pTNM system [37]. The study was approved by the local Ethical Committee (Ethical Committee of the Padua Teaching Hospital, Approved Protocol Number: P.448) and all patients providing written informed consent were prospectively registered in the First Surgical Clinic Tissue Biobank database at the Padua Hospital, according to national and international guidelines.

Cell lines and culture conditions

Two colon cell lines with different extent of SerpinB3 expression were preliminary selected: the HTC15 (ATCC CCL-225) and the more undifferentiated HT29 (ATCC HTB-38) cell lines [3840]. In some experiments recombinant SerpinB3 (rSerpinB3) was also used overnight at 200ng/ml concentration to assess its paracrine effect on these cell lines. As positive control, the HepG2 cell line (ATCC-HB-8065) stably transfected to overexpress SerpinB3 [12] was used, while HepG2 cells transfected with the plasmid alone and expressing trivial levels of SerpinB3 were used as negative control (HepG2/Control). The HepG2 transfected cells are regularly tested for SerpinB3 expression by RT-PRC and by immunofluorescence at each thawing of new frozen vials. HTC15 cells were cultured in RPMI 1640 medium (ThermoFisher Scientific, Milan, Italy) and HT29 cells were cultured in McCoy's Modified Medium (ThermoFisher Scientific) either supplemented with 10% heat-inactivated fetal calf serum (FCS, ThermoFisher Scientific), 20 mM L-glutamine (Sigma Aldrich, Milano, Italy), and 100 U/mL streptomycin. HepG2/Control and HepG2/SerpinB3 cells were maintained in standard medium supplemented with 1 μg/mL Geneticin (G418; Sigma Aldrich, Milano, Italy) as previously described [12]. Each cell line was plated with a density of 400.000 cells/well, maintained in a humidified 5% CO2 incubator at 37°C and after 24, 48 and 72 hour incubation cells lines were harvested and washed with 1× PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2 HPO4, 2 mM KH2 PO4, pH 7.2).

The real time cell analyzer (RTCA, xCELLigence, ACEA Biosciences) was used for real-time cell proliferation and invasion analysis. Briefly, cellular proliferation was measured as impedance-based signals, reflecting cell adherence. To measure cellular invasion cells were plated on top of an upper chamber equipped with 8-μm porosity filter coated with Matrigel 1:20 in basal medium (BD, Biosciences). As cells moved towards the lower chamber, containing fetal bovine serum as chemo-attractant, they adhered to gold impedance microelectrodes, determining a change in the impedance signal. The Cell Index, reflecting the cell number present in well, was monitored every 10 minutes and calculated as the relative change of electrical impedance caused by migrated cells using the RTC software (version 1.2, Roche Diagnostics). All the results were expressed as mean of experiments performed in quadruplicate.

RNA isolation and real-time PCR

Extraction of total cellular RNA and reverse transcription were carried out according to a previously published protocol [41]. Total RNA was reverse transcribed using SuperScript III reverse transcriptase (Invitrogen) for 3hr at 55 °C. For SerpinB3 and β-Catenin genes specific sense and antisense primers were used as previously described [15], while for COX-2 the following primers were used: forward 5′ TCA AAT GAG ATT GTG GAA AAA T'3 and reverse 5′ AGA TCA TCT CTG CCT GA GTA TCT T '3. To quantify the amount of mRNA in each sample, a standard reference curve was realized using serial 5-fold dilutions of HT29 cDNA (from 10 to 0.003 pg/reaction). Hypoxanthine guanine phosphoribosyl transferase 1 (HPRT1) did not show statistically significant difference between tumor and non-tumor mucosa and it was chosen as housekeeping gene. Each sample was run in duplicate and expression data were normalized to 103 copies of HPRT1. The results were reported as ng of expressed mRNA [42].

In some representative cases, quantitative results obtained by Real-Time PCR were confirmed by the LabChip® Systems (LabChip® GX Touch for Genomics, PerkinElmer, Milan, Italy), according to the manufacturer's instructions.

Protein expression

The expression of each protein was detected by Western blot using the following monoclonal primary antibodies against: SerpinB3/SCCA1 (clone 8H11, 2μg/mL Santa Cruz Biotechnology, Heidelberg, Germany; Hepa-Ab, 8 μg/mL, Xeptagen, Venice, Italy), COX-2 (clone MTC02, 2 μg/mL, Santa Cruz Biotechnology, Heidelberg, Germany), β-Catenin (clone 17C2, 0.4 μg/mL, Novacastra, Leica Biosystems, Newcastle, UK) and β-actin (clone AC15, 0.018–10 μg/mL, Sigma Aldrich, Milan, Italy). Nuclear and cytosolic extracts were prepared by lysing HTC15 and HT29 cells in ice with isolation buffer (250 mM sucrose, 10mM tris-HCl, o,1 mM EGTA, pH7,4) including phosphatase and protease inhibitors. Cells were mechanically homogenized with pestles and centrifuged at 900g for 10 minutes. Pellet containing nuclei was resuspended in RIPA lysys buffer (Millipore) and supernatant containing cytoplasm was added with 0,5% Triton X-100. For immunoblotting analysis 30 ug of total lysates or of cellular fractions cells were loaded on 10% SDS-polyacrylamide gels and proteins were blotted on nitrocellulose membranes following standard methods. Nuclear matrix protein P84 and GAPDH were used to normalize protein extracts expression. After incubation with the different antibodies, the results were visualized by the enhanced chemiluminescence method using standard protocols (Pierce Biotechnology, Rockford, USA).

Immunohistochemistry was carried out on 3-μm thick paraffin sections of tumor and non tumor samples of 16 patients. Images of representative fields were captured by Leica Qwin Plus v3 software, under a CCD camera connected to a Leica M165FC microscope (Microsystem Imaging Solutions Ltd. Milan, Italy). The immunoreactivity was semi-quantified using the x JmageJ software (https://imagej.nih.gov/). Positivity was expressed as percentage of positive areas over total area. Data represent the average of all the 6 fields acquired for each analyzed section. Staining specificity was confirmed by replacing primary antibody with PBS.

For immunofluorescence analysis cells were seeded on slides (5×105 cells/well) in a maximum volume of 3 mL/well, cultured for 2 days and then fixed in 4% paraformaldehyde. Primary antibodies described above were used, followed by appropriate secondary antibodies at room temperature for 60 min, TRITC-conjugated anti-rabbit antibody and FITC-conjugated anti-mouse antibody (1 μg/mL; Dako, Copenhagen, Denmark). Nuclei were stained with Hoechst 33342 (20 μg/mL; Sigma Aldrich, Milan, Italy). Slides were analyzed using a video-confocal fluorescence microscope ViCo C2 (Nikon, Florence, Italy) equipped with a triple band pass filter set (FITC, TRITC, DAPI). Mean fluorescence intensity in regions of interest (ROI) was measured by using the ImageJ/Fiji ROI Manager.

Statistical analysis

All data were presented as mean±standard error (SE) of the mean and were analyzed by Mann–Whitney U test, Spearman rank correlation test, when appropriated, using GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, CA) and Social Sciences (SPSS, version 20.0, Chicago, USA). A P value < 0.05 was considered statistically significant. Student's t-test was applied to determine statistical significance between different time points ( 24hr versus 48hr - 72hr and 48hr versus 72hr) in the four cell lines. All statistical tests were two-sided (see Supplementary Material and Methods).

SUPPLEMENTARY MATERIALS FIGURES AND TABLES

Acknowledgments

We are deeply grateful to Dr. Santina Quarta for providing the transfected HepG2 cell lines, to Dr. Cristian Turato for scientific and technical support, to Dr. Elisabetta Faggin for technical advices and immunohistochemistry reagents. We are also grateful to Dr. Giorgio Fassina (Xeptagen, Italy) for providing the anti-SCCA1 antibody.

Footnotes

CONFLICTS OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

GRANT SUPPORT

The study was supported in part by the following grants: National Ministry of Education, University and Research (FIRB Project Prot. RBLA03S4SP_005), University of Padua [Project No. STPD11RYPT_003] and Associazione Italiana per la Ricerca sul Cancro (AIRC Project No 10235).

REFERENCES

1. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;29:418–22. [PubMed]
2. Pretlow TP, Pretlow TG. Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim Biophys Acta. 2005;1756:83–96. [PubMed]
3. Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev. 2010;31:31–8. [PMC free article] [PubMed]
4. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S. Specific Mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF-wild-type colorectal cancers. Clin Cancer Res. 2012;18:4753–63. [PMC free article] [PubMed]
5. Inoue Y, Saigusa S, Iwata T, Okugawa Y, Toiyama Y, Tanaka K, Uchida K, Mohri Y, Kusunoki M. The prognostic value of KRAS mutations in patients with colorectal cancer. Oncol Reports. 2012;28:1579–84. [PubMed]
6. Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol. 2013;26:825–34. [PubMed]
7. Remold-O'Donnell E. The ovalbumin family of serpin proteins. FEBS Lett. 1993;315:105–8. [PubMed]
8. Catanzaro JM, Sheshadri N, Pan JA, Sun Y, Shi C, Li J, Powers RS, Crawford HC, Zong WX. Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun. 2014;5:3729. [PMC free article] [PubMed]
9. Pontisso P. Role of SERPINB3 in hepatocellular carcinoma. Ann Hepatol. 2014;13:722–7. [PubMed]
10. Suminami Y, Nagashima S, Vujanovic NL, Hirabayashi K, Kato H, Whiteside TL. Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1. Br J Cancer. 2000;82:981–9. [PMC free article] [PubMed]
11. Ciscato F, Sciacovelli M, Villano G, Turato C, Bernardi P, Rasola A, Pontisso P. SERPINB3 protects from oxidative damage by chemotherapeutics through inhibition of mitochondrial respiratory complex I. Oncotarget. 2014;5:2418–27. doi: 10.18632/oncotarget.1411. [PMC free article] [PubMed] [Cross Ref]
12. Quarta S, Vidalino L, Turato C, Ruvoletto M, Calabrese F, Valente M, Cannito S, Fassina G, Parola M, Gatta A, Pontisso P. SerpinB3 induces epithelial-mesenchymal transition. J Pathol. 2010;221:343–56. [PubMed]
13. Cannito S, Turato C, Paternostro C, Biasiolo A, Colombatto S, Cambieri I, Quarta S, Novo E, Morello E, Villano G, Fasolato S, Musso T, David E, et al. Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells. Oncotarget. 2015;6:2206–21. doi: 10.18632/oncotarget.2943. [PMC free article] [PubMed] [Cross Ref]
14. Turato C, Vitale A, Fasolato S, Ruvoletto M, Terrin L, Quarta S, R Ramirez Morales, Biasiolo A, Zanus G, Zali N, Tan PS, Hoshida Y, Gatta A, et al. SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer. 2014;11:2708–15. [PMC free article] [PubMed]
15. Hu J, Shao S, Song Y, Zhao J, Dong Y, Gong L, Yang P. Hepatocyte growth factor induces invasion and migration of ovarian cancer cells by decreasing the expression of E-cadherin, beta-catenin, and caveolin-1. Anat Rec (Hoboken) 2010;293:1134–39. [PubMed]
16. Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell. 2012;21:66–81. [PMC free article] [PubMed]
17. Suraweera N, Robinson J, Volikos E, Guenther T, Talbot I, Tomlinson I, Silver A. Mutations within Wnt pathway genes in sporadic colorectal cancers and cell lines. Int J Cancer. 2006;119:1837–42. [PubMed]
18. Voloshanenko O, Erdmann G, Dubash TD, Augustin I, Metzig M, Moffa G, Hundsrucker C, Kerr G, Sandmann T, Anchang B, Demir K, Boehm C, Leible S, et al. Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nat Commun. 2013;4:2610–22. [PMC free article] [PubMed]
19. Park JK, Song JH, He TC, Nam SW, Lee JY, Park WS. Overexpression of Wnt-2 in colorectal cancers. Neoplasma. 2009;56:119–23. [PubMed]
20. Bocca C, Ievolella M, Autelli R, Motta M, Mosso L, Torchio B, Bozzo F, Cannito S, Paternostro C, Colombatto S, Parola M, Miglietta A. Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness. Expert Opin Ther Targets. 2014;18:121–35. [PubMed]
21. Roelofs HM, RH Te Morsche, Van Heumen BW, Nagengast FM, Peters WH. Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterol. 2014;2:14–21. [PMC free article] [PubMed]
22. Lim JW, Kim H, Kim KH. Nuclear factor-kappaB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab Invest. 2001;81:349–60. [PubMed]
23. Ulivi V, Cancedda R, Cancedda FD. 15-deoxy-delta 12 14-prostaglandin J (2) inhibits the synthesis of the acute phase protein SIP24 in cartilage: Involvement of COX-2 in resolution of inflammation. J Cell Physiol. 2008;217:433–41. [PubMed]
24. Shao J, Jung C, Liu C, Sheng H. Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J Biol Chem. 2005;280:26565–72. [PubMed]
25. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 2003;63:728–34. [PubMed]
26. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS, Ogino S. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia. 2007;9:569–577. [PMC free article] [PubMed]
27. Nuñez F, Bravo S, Cruzat F, Montecino M, De Ferrari GV. Wnt/β-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells. PLoS One. 2011;6:e18562. [PMC free article] [PubMed]
28. Shafie NH, N Mohd Esa, Ithnin H, A Md Akim, Saad N, Pandurangan AK. Preventive inositol hexaphosphate extracted from rice bran inhibits colorectal cancer through involvement of Wnt/β-catenin and COX-2 pathways. Biomed Res Int. 2013. p. 681027. [PMC free article] [PubMed]
29. Kazem A, Sayed KE, Kerm YE. Prognostic significance of COX-2 and β-catenin in colorectal carcinoma. Alexandria Journal of Medicine. 2014;50:2011–20.
30. SR Da Silva, Matos D, Waitzberg AF, et al. Study of APC and β-catenin protein expression in polyps and colorectal adenocarcinoma. Applied Cancer Res. 2011;31:81–6.
31. Hegazy RA, Hegazy AA, Abdel-Aziz HR, et al. Expression of β-Catenin and Cyclooxygenase 2 in colorectal Carcinoma: An Immunohistochemical Study. Univ J Med Sci. 2013;1:72–7.
32. Roelofs HM, RH Te Morsche, van Heumen BW, Nagengast FM, Peters WH. Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterology. 2014;2:14–21. [PMC free article] [PubMed]
33. Milner BL, Penny CB, Gibbon VE, Kay P, Ruff P. CD133/EpCAM Cancer Stem Cell Markers of Tumour Stage in Colorectal Cancer Cells. J Tissue Sci Eng. 2014;6:143.
34. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF. Cancer stem cells from colorectal cancer-derived cell lines. PNAS. 2010(107):3722–27. [PubMed]
35. Villano G, Turato C, Quarta S, Ruvoletto M, Ciscato F, Terrin L, Semeraro R, Paternostro C, Parola M, Alvaro D, Bernardi P, Gatta A, Pontisso P. Hepatic progenitor cells express SerpinB3. BMC Cell Biol. 2014(15):5. [PMC free article] [PubMed]
36. Sheshadri N, Catanzaro JM, Bott AJ, Sun Y, Ullman E, Chen EI, Pan JA, Wu S, Crawford HC, Zhang J, Zong WX. SCCA1/SERPINB3 promotes oncogenesis and epithelial-mesemchymal transition via the unfolded protein response and IL6 signaling. Cancer Res. 2014(74):1–12. [PMC free article] [PubMed]
37. American Joint . Committee on Cancer Staging Manual 7th ed. New York, NY: Springer; 2010. pp. 143–164.
38. Vermeulen SJ, Chen TR, Speleman F, Nollet F, Van Roy FM, Mareel MM. Did the four human cancer cell lines DLD-1, HCT-15, HCT-8, and HRT-18 originate from one and the same patient? Cancer Genet Cytogenet. 1998;107:76–9. [PubMed]
39. Kawai K, Viars C, Arden K, Tarin D, Urquidi V, Goodison S. Comprehensive karyotyping of the HT-29 colon adenocarcinoma cell line. Genes Chromosomes Cancer. 2002;34:1–8. [PubMed]
40. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013;2:e71. [PMC free article] [PubMed]
41. Terrin L, J Dal Col, Rampazzo E, Zancai P, Pedrotti M, Ammirabile G, Bergamin S, Rizzo S, Dolcetti R, De Rossi A. Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B-lymphocytes. J Virol. 2008;82:10175–87. [PMC free article] [PubMed]
42. Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R, Esposito G, DelBianco P, Nitti D, De Rossi A. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res. 2008;14:7444–51. [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC